This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Rilutek (riluzole)
General Description:
Rilutek (riluzole) is an oral medication used for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord.
Riluzole works by inhibiting glutamate release, which helps protect motor neurons from excitotoxicity, slowing disease progression and potentially extending survival in ALS patients.
Disease Indications:
Amyotrophic Lateral Sclerosis (ALS)
Manufacturer:
Sanofi – Aventis Groupe
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
• Medicines & Healthcare products Regulatory Agency (MHRA)
• Medsafe (New Zealand)
Package:
• 50 mg × 56 tablets
Shipping:
Room Temperature Shipping
Rilutek is stable at room temperature and does not require refrigeration. It is shipped under standard shipping conditions (15°C to 25°C), ensuring the tablets remain effective and safe throughout transit.
This standard shipping method is cost-effective while maintaining the medication’s integrity and therapeutic activity.
How to Access Rilutek (riluzole) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Rilutek (riluzole) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
